Tensive lands €20M EIB convertible loan to bring bioresorbable breast implant to market
What's the deal? Milan-based Tensive has signed a convertible loan agreement of up to €20 million with the European Investment Bank (EIB) to commercialise REGENERA™, its bioresorbable scaffold for breast reconstruction. The clinical-stage biomaterials company develops implants that regenerate natural tissue after breast cancer lumpectomy.
The terms: The convertible loan is drawable in two tranches — €8 million and €12 million — each maturing 20 years from drawdown. It is backed by the European Commission's InvestEU programmeDealroom has a profile for this one. Try Dealroom →.
Where the money goes: Proceeds fund research, clinical studies, CE marking, manufacturing scale-up, and commercialisation of REGENERA™. The €20 million covers half of Tensive's €40 million plan to carry the product through EU approval and launch; it is in talks with institutional investors and strategic partners for the rest.
Why now? The financing follows positive clinical results. On July 28, 2026, Tensive reported 12-month data from its pivotal trial covering all 94 enrolled patients, with good-to-excellent cosmetic outcomes in 94.2% of evaluable cases. Five-year follow-up from its first-in-human study shows persistent volume replacement and no capsule formation.
What's the endgame? Tensive anticipates EU regulatory approval of REGENERA™ as soon as early 2027. "We are one step closer to offering the first natural, lasting solution to women who today have no viable options for reconstruction after breast cancer lumpectomy," said chief executive officer Sanjay Kakkar.
What could go wrong? Each tranche is subject to financial and contractual conditions in the agreement, and Tensive still needs to secure the other half of its €40 million plan. Regulatory approval, though anticipated for early 2027, is not guaranteed.
The signal: At roughly $23.2 million, the round ranks in the 98th percentile among convertible deals in Italian nanotech, underscoring the EIB's push to back European women's health technology. "Supporting European innovation in health, and in women's health in particular, is central to the EIB Group's mission," said EIB vice president Gelsomina Vigliotti.
Image credit: Generated with Gemini
